HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Everolimus

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
Also Known As:
40-O-(2-hydroxyethyl)-rapamycin; Afinitor; Certican; RAD 001; RAD001; SDZ RAD; SDZ-RAD; 001, RAD; RAD, SDZ; Zortress
Networked: 4115 relevant articles (590 outcomes, 1414 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Serruys, Patrick W: 97 articles (07/2023 - 05/2005)
2. Stone, Gregg W: 53 articles (01/2022 - 06/2006)
3. Onuma, Yoshinobu: 48 articles (01/2022 - 03/2008)
4. Motzer, Robert J: 47 articles (01/2022 - 12/2006)
5. Windecker, Stephan: 45 articles (01/2024 - 07/2010)
6. Sabaté, Manel: 36 articles (07/2023 - 12/2011)
7. Valgimigli, Marco: 35 articles (01/2024 - 12/2011)
8. Escudier, Bernard: 34 articles (01/2022 - 08/2008)
9. Brugaletta, Salvatore: 33 articles (07/2023 - 12/2011)
10. Choueiri, Toni K: 30 articles (01/2023 - 05/2011)

Related Diseases

1. Neoplasms (Cancer)
2. Breast Neoplasms (Breast Cancer)
3. Renal Cell Carcinoma (Grawitz Tumor)
4. Neuroendocrine Tumors (Neuroendocrine Tumor)
5. Primitive Neuroectodermal Tumors (PNET)

Related Drugs and Biologics

1. TOR Serine-Threonine Kinases
2. Everolimus
3. Sirolimus (Rapamycin)
4. Sunitinib (Sutent)
5. trans-sodium crocetinate (crocetin)
6. Hormones (Hormone)
7. exemestane (Aromasin)
8. Octreotide (Sandostatin)
9. Sorafenib (BAY 43-9006)
10. temsirolimus

Related Therapies and Procedures

1. Therapeutics
2. Stents
3. Drug Therapy (Chemotherapy)
4. Radiotherapy
5. Aftercare (After-Treatment)